PMH61 ADULTS WITH ATTENTION-DEFICIT/ HYPERACTIVITY DISORDER (ADHD) IN GERMANY—PREVALENCE, COMORBIDITIES AND PHARMACOTHERAPY IN PRACTICE  by Slawik, L & Rudolph, I
future research in drug classes other than antidepressants should
be conducted to verify our ﬁndings.
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OBJECTIVES: Because prescribing in routine clinical practice
reﬂects both the physicians’ perception of the efﬁcacy and safety
of a drug and the patient’s characteristics, this study aimed at
comparing the real-life proﬁle of patients prescribed escitalo-
pram, SSRIs or venlafaxine in primary care in order to better
understand drugs-related determinants of prescription.
METHODS: This retrospective study used data from the General
Practitioners Research Database and included adult patients with
an incident prescription (no antidepressant in the previous12-
month) of escitalopram, an SSRI or venlafaxine between January
1, 2003 and June 30, 2005, and an associated diagnosis of
depression. Demographics, disease and treatment characteristics,
and health care resource consumption were assessed in the
12-month before the new prescription and compared across
treatment groups. RESULTS: A total of 6,910 patients were
prescribed escitalopram, 47,853 SSRIs and 2,832 venlafaxine.
Compared with SSRIs-treated patients, escitalopram-treated
patients were younger (p = 0.001), more often diagnosed with
severe depression (p = 0.018), and more often suffering from
associated anxiety (p < 0.001). They also had more hospitalisa-
tions (p = 0.021), referrals (p = 0.020), anxiolytics (p < 0.001)
and hypnotics (p < 0.001) prescriptions at baseline. Compared
with venlafaxine-treated patients, escitalopram-treated patients
were younger (p < 0.001), less often diagnosed with severe
depression (p < 0.001) and concomitant anxiety (p < 0.001), and
had lighter psychiatric history (p = 0.002). However, they were
more often suffering from cardio-respiratory diseases (p = 0.02).
Baseline resource use was sensibly similar between treatment
groups. CONCLUSIONS: Important differences in patients’ pro-
ﬁles were observed between escitalopram, generic SSRIs and
venlafaxine, and correspond to current data on the drugs’ efﬁ-
cacy and safety proﬁle: physicians prescribed escitalopram and
venlafaxine to patients with more severe depression. The subse-
quent choice between escitalopram and venlafaxine was based on
safety proﬁles, escitalopram being perceived as safer and being
prescribed to patients with a heavier somatic background. These
differences have to be adjusted for in further real-life drug effec-
tiveness studies otherwise they can importantly bias the results.
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OBJECTIVES: Awareness of adult ADHD is low. Even though
guidelines have existed in Germany since 2003, diagnosis and
treatment are not standardized and remain difﬁcult in practice,
often complicated by comorbidities. This analysis investigates
prevalent psychiatric comorbidities and the applied pharmaco-
therapy of adult patients with ADHD diagnosed by general prac-
titioners (GPs) or by neurologists/psychiatrics (NPs) in Germany
in 2007. METHODS: A retrospective database analysis of adult
patients aged 19–59 diagnosed with ADHD (ICD-10 code F90)
was performed, using the IMS Disease Analyzer that contains
electronic medical records of representative panels of German
GPs and NPs, capturing drug prescription and diagnoses.
RESULTS: Patients were identiﬁed through the records of NPs
seeing 122,666 patients and GPs seeing 1.16 million patients,
aged 19–59. NPs diagnosed ADHD in 851 adults (annual preva-
lence 0.69%, 60% male), of which 521 had at least one psychi-
atric co-diagnosis (33% mood disorders F30-39, 19% neurotic,
stress-related and somatoform disorders F40-48). In 214 of 493
GPs’ ADHD patients (annual prevalence 0.04%, 61% male), at
least one psychiatric disorder was co-diagnosed (18% F30-39,
19% F40-48). A total of 48.8% of the NPs’ patients (27.2% of
the GPs’) without a psychiatric comorbidity were treated with
Methylphenidate (MPH) and 5.8% (0.4%) with MPH plus at
least one antidepressant prescription. Treatment differed in
patients with psychiatric comorbidities of which 22.1% (14.0%)
received MPH, but 18.6% (9.8%) MPH plus at least one anti-
depressant. NPs treated other 186 (GPs 142) patients without
diagnosed ADHD (F90) with MPH. CONCLUSIONS: Adminis-
trative prevalence of adult ADHD was low compared to data
derived from literature and both prevalence and comorbidity
proﬁle differed in age, gender and specialist. The pharmaco-
therapy of GPs and NPs depended on prevalent comorbidities
but did not show consistency according to guidelines. A further
understanding of adult ADHD and its treatment opportunities is
needed.
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OBJECTIVES: To describe the frequency of physical injuries and
compare the costs of care from a United States (US) payer per-
spective before and after emergent epilepsy care. METHODS:
This retrospective claims database analysis utilized the PHAR-
Metrics database from 90 regional US health plans. Patients
received care between July 1, 2005 and June 30, 2006 in an
ambulance, emergency room, or inpatient hospital with an
Episode Treatment Grouper of epilepsy without surgery. The
index date was the earliest date of emergent epilepsy care with a
study period of 6 months pre and post-index. Eligible patients
had at least one diagnosis for epilepsy (ICD-9-CM 345.xx,
excluding 345.6) were 12–64 years of age, received 145 days
supply of antiepileptic drugs without emergent care for epilepsy
in the pre-index period, and had continuous eligibility for 6
months pre-index and post-index. Injuries coded on the index
date were described according to ICD-9-CM groupings. Total
epilepsy-related, and non-epilepsy-related direct medical costs
paid to the provider were compared before and after index date
using non-parametric tests for paired samples. Injury-related
costs were also described. RESULTS: A total of 9.4% (n = 146)
of the 1213 patients receiving emergent care for a seizure event
experienced a co-occurring injury on the same date. The majority
of injuries were comprised of superﬁcial injuries and contusions
(28%), fractures (21%), open wounds or injury to blood vessels
(19%) intracranial injury (10%), and/or medication toxicity
(10%). Both per patient non-epilepsy-related (mean =
$3997.23US) and epilepsy-related (mean = US$992.30) direct
medical costs of care pre-index were signiﬁcantly different
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